The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Targeting T Cell Co-receptors for Cancer Therapy
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 1×
“The response rate for nivolumab was 20%, and in this study, PD-L1 status did not correlate with clinical outcome (Brahmer et al., 2015).”
BackgroundCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“BMS-936559 (Brahmer et al., 2012; Topalian et al., 2012).”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Cited by
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Self-citationDefining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
Ivashkiv, L. B. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0029-z · Cited by 1,358
André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,221
Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment
Ma, X., Bi, E., Lu, Y., Su, P., Huang, C., Liu, L., Wang, Q., Yang, M., Kalady, M. F., Qian, J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.04.002 · Cited by 1,033
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
Kamphorst, A. O., Pillai, R. N., Yang, S., Nasti, T. H., Akondy, R. S., Wieland, A., Sica, G. L., Yu, K., Koenig, L., Patel, N. T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705327114 · Cited by 854
“Antibodies that block the PD-1 pathway have demonstrated antitumor activity in cancer patients, and are now an approved treatment of several different cancers (8).”
BackgroundJuneja, V. R., McGuire, K. A., Manguso, R. T., LaFleur, M. W., Collins, N., Haining, W. N., Freeman, G. J., & Sharpe, A. H. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160801 · Cited by 851
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
Cancer immunotherapies targeting the PD-1 signaling pathway
Iwai, Y., Hamanishi, J., Chamoto, K., & Honjo, T. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0329-9 · Cited by 635
Tumeh, P. C., Hellmann, M. D., Hamid, O., Tsai, K. K., Loo, K. L., Gubens, M. A., Rosenblum, M., Harview, C. L., Taube, J. M., Handley, N., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0325 · Cited by 560
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
Immune checkpoints and their inhibition in cancer and infectious diseases
Dyck, L., & Mills, K. H. G. (2017) · European Journal of Immunology · doi:10.1002/eji.201646875 · Cited by 541
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Cheng, A.-L., Hsu, C., Chan, S. L., Choo, S.-P., & Kudo, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.025 · Cited by 528
Targeting the microenvironment in solid tumors
Belli, C., Trapani, D., Viale, G., D'Amico, P., Duso, B. A., Della Vigna, P., Orsi, F., & Curigliano, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.004 · Cited by 496
Wang, P.-F., Chen, Y., Song, S.-Y., Wang, T.-J., Ji, W.-J., Li, S.-W., Liu, N., & Yan, C.-X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00730 · Cited by 468
PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
Salmaninejad, A., Valilou, S. F., Shabgah, A. G., Aslani, S., Alimardani, M., Pasdar, A., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28358 · Cited by 445
T‐cell exhaustion in HIV infection
Fenwick, C., Joo, V., Jacquier, P., Noto, A., Banga, R., Perreau, M., & Pantaleo, G. (2019) · Immunological Reviews · doi:10.1111/imr.12823 · Cited by 425
Nicolas-Boluda, A., Vaquero, J., Vimeux, L., Guilbert, T., Barrin, S., Kantari-Mimoun, C., Ponzo, M., Renault, G., Deptula, P., Pogoda, K., et al. (2021) · eLife · doi:10.7554/elife.58688 · Cited by 368
Holmgaard, R. B., Schaer, D. A., Li, Y., Castaneda, S. P., Murphy, M. Y., Xu, X., Inigo, I., Dobkin, J., Manro, J. R., Iversen, P. W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0356-4 · Cited by 356
“…strategies such as immune check-point blockade have shown significant promise for treat-ment of cancers resistant to conventional modalities, leading to Food and Drug Administration (FDA) approval in advanced melanoma, renal cell carcinoma and non-small cell lung cancer (NSCLC) [52].”
Bengsch, B., Ohtani, T., Khan, O., Setty, M., Manne, S., O’Brien, S., Gherardini, P. F., Herati, R. S., Huang, A. C., Chang, K.-M., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.026 · Cited by 318
Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs
Hewitt, S. L., Bai, A., Bailey, D., Ichikawa, K., Zielinski, J., Karp, R., Apte, A., Arnold, K., Zacharek, S. J., Iliou, M. S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat9143 · Cited by 316
“Systemically administered checkpoint inhibitors (CPIs) have improved metastatic disease survival by targeting the T cell co-inhibitory pathways of CTLA-4 and PD-1/PD-L1 (1).”
BackgroundMenk, A. V., Scharping, N. E., Rivadeneira, D. B., Calderon, M. J., Watson, M. J., Dunstane, D., Watkins, S. C., & Delgoffe, G. M. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171068 · Cited by 313
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Ruf, B., Heinrich, B., & Greten, T. F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00572-w · Cited by 312
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3311 · Cited by 308
“Generally, immune checkpoint blockade aims to support the activation of antitumor T cells (42).”
BackgroundNAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion
Lv, H., Lv, G., Chen, C., Zong, Q., Jiang, G., Ye, D., Cui, X., He, Y., Xiang, W., Han, Q., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.021 · Cited by 301
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
Zhang, Q., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.017 · Cited by 296
Metabolic Modulation in Macrophage Effector Function
Diskin, C., & Pålsson-McDermott, E. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00270 · Cited by 291
Antitumor effects of immunity-enhancing traditional Chinese medicine
Wang, Y., Zhang, Q., Chen, Y., Liang, C.-L., Liu, H., Qiu, F., & Dai, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109570 · Cited by 287
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Lee, J. Y., Lee, H. T., Shin, W., Chae, J., Choi, J., Kim, S. H., Lim, H., Won Heo, T., Park, K. Y., Lee, Y. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms13354 · Cited by 285
Hu, W., Zi, Z., Jin, Y., Li, G., Shao, K., Cai, Q., Ma, X., & Wei, F. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2281-2 · Cited by 265
Okkenhaug, K., Graupera, M., & Vanhaesebroeck, B. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0716 · Cited by 264
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
Tan, C. L., Kuchroo, J. R., Sage, P. T., Liang, D., Francisco, L. M., Buck, J., Thaker, Y. R., Zhang, Q., McArdel, S. L., Juneja, V. R., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20182232 · Cited by 258
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease
Attanasio, J., & Wherry, E. J. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.022 · Cited by 256
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Tan, S., Zhang, H., Chai, Y., Song, H., Tong, Z., Wang, Q., Qi, J., Wong, G., Zhu, X., Liu, W. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14369 · Cited by 255
Kim, C. G., Jang, M., Kim, Y., Leem, G., Kim, K. H., Lee, H., Kim, T.-S., Choi, S. J., Kim, H.-D., Han, J. W., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aay0555 · Cited by 245
The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
Huff, W. X., Kwon, J. H., Henriquez, M., Fetcko, K., & Dey, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112810 · Cited by 217
“On the other hand, the use CD28 agonists to awaken T cells from the tolerant state could lead to new therapies to re-activate the immune system for the treatment of infectious disease [61] and cancer [62].”
BackgroundExtracellular Matrix Cues Regulate Mechanosensing and Mechanotransduction of Cancer Cells
Mierke, C. T. (2024) · Cells · doi:10.3390/cells13010096 · Cited by 146
Pai, C.-C. S., Huang, J. T., Lu, X., Simons, D. M., Park, C., Chang, A., Tamaki, W., Liu, E., Roybal, K. T., Seagal, J., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.006 · Cited by 141
“In recent years, immune checkpoint inhibitors have been rapidly approved for the management of advanced malignancies, including melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), urothelial carcinoma, and head and neck cancer (Callahan et al., 2016).”
Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids
Tokunaga, A., Sugiyama, D., Maeda, Y., Warner, A. B., Panageas, K. S., Ito, S., Togashi, Y., Sakai, C., Wolchok, J. D., & Nishikawa, H. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190738 · Cited by 124
PD‐1 suppresses TCR‐CD8 cooperativity during T‐cell antigen recognition
Li, K., Yuan, Z., Lyu, J., Ahn, E., Davis, S. J., Ahmed, R., & Zhu, C. (2021) · Nature Communications · doi:10.1038/s41467-021-22965-9 · Cited by 81
Gestermann, N., Saugy, D., Martignier, C., Tillé, L., Fuertes Marraco, S. A., Zettl, M., Tirapu, I., Speiser, D. E., & Verdeil, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1736792 · Cited by 69
Metadata
- Authors
- Callahan, M. K., Postow, M. A., & Wolchok, J. D.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 44
- Issue
- 5
- Pages
- 1069-1078
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2406612864
- Cited by
- 469
- References
- 76
- FWCI
- 32.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.